![Kathryn Gallaway, MD (@ke_gallaway) 's Twitter Profile](https://pbs.twimg.com/profile_images/1691639298133770241/XaTouUs5_200x200.jpg)
Kathryn Gallaway, MD
@ke_gallaway
34 y/o G2P2 presents w/ insatiable thirst for knowledge of unknown etiology | Philosophy @RiceUniversity | MD @UTSWNews | Associate Medical Director @DAVAOnc
ID: 1558842292605259777
https://www.linkedin.com/in/kathryn-gallaway-845136236/ 14-08-2022 15:46:19
958 Tweet
383 Followers
917 Following
![Kathryn Gallaway, MD (@ke_gallaway) 's Twitter Profile Photo Kathryn Gallaway, MD (@ke_gallaway) 's Twitter Profile Photo](https://pbs.twimg.com/profile_images/1691639298133770241/XaTouUs5_200x200.jpg)
Exciting early results for synergistic combination of IRAK4i and BTKi in PCNSL presented by Christopher D'Angelo in our uncommon lymphoma session Expansion cohort for TakeAim Lymphoma trial is currently enrolling! clinicaltrials.gov/study/NCT03328…
![Kathryn Gallaway, MD (@ke_gallaway) on Twitter photo Exciting early results for synergistic combination of IRAK4i and BTKi in PCNSL presented by <a href="/crdangelo9/">Christopher D'Angelo</a> in our uncommon lymphoma session
Expansion cohort for TakeAim Lymphoma trial is currently enrolling!
clinicaltrials.gov/study/NCT03328… Exciting early results for synergistic combination of IRAK4i and BTKi in PCNSL presented by <a href="/crdangelo9/">Christopher D'Angelo</a> in our uncommon lymphoma session
Expansion cohort for TakeAim Lymphoma trial is currently enrolling!
clinicaltrials.gov/study/NCT03328…](https://pbs.twimg.com/media/GUo6KtvXkAAySit.jpg)